Philippe J. Amouyal's most recent trade in Cava Group Inc was a trade of 1,767 Common Stock done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cava Group Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 1,767 | 18,074 | - | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 103,806 | 103,806 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 89,312 | 89,312 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 285,174 (0%) | 0% | 0 | Common Stock | |
| Cava Group Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,307 | 16,307 | - | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 248,364 (0%) | 0% | 0 | Common Stock | |
| Cava Group Inc | Philippe J. Amouyal | Director | Purchase of securities on an exchange or from another person at price $ 33.18 per share. | 17 Nov 2023 | 10,000 | 15,000 | - | 33.2 | 331,800 | Common Stock |
| Cava Group Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 5,000 | 5,000 | - | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock |